ALKS Stock Analysis: Alkermes | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 8.770m USD | 12M Return: 74.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 117M
EPS Trend: 70.4%
Qual. Beats: 1
Rev. Trend: -31.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alkermes plc is an Ireland-based biopharmaceutical company headquartered in Dublin that develops and commercializes treatments for central nervous system (CNS) disorders and addiction. The companys commercial portfolio focuses on schizophrenia, bipolar I disorder, alcohol and opioid dependence, and narcolepsy-related conditions, with marketed products including ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ.
In addition to its proprietary products, Alkermes maintains a pipeline of clinical and preclinical candidates targeting neurological disorders and licenses its proprietary drug delivery technology platforms to third parties for use in their own development and manufacturing efforts. The company has long-standing collaboration agreements with Janssen Pharmaceutica and operates primarily in the United States, Ireland, and international markets.
As a mid-cap biotechnology company, Alkermes operates within a sector that depends heavily on patent protection, FDA regulatory approvals, and sustained R&D investment. Its dual business model-combining proprietary drug development with technology platform licensing-is a common approach in specialty CNS-focused pharma, allowing companies to diversify revenue streams while concentrating expertise in a defined therapeutic area. Ireland is a frequent corporate domicile for pharmaceutical firms due to the countrys established life sciences ecosystem and favorable corporate tax framework.
- LUMRYZ launch drives revenue growth in narcolepsy franchise
- Janssen royalty revenue from Invega underpins operating margins
- ARISTADA and LYBALVI sales offset VIVITROL generic pressure
| Net Income: 152.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -17.92 > 1.0 |
| NWC/Revenue: 48.59% < 20% (prev 68.39%; Δ -19.80% < -1%) |
| CFO/TA 0.06 > 3% & CFO 256.2m > Net Income 152.7m |
| Net Debt (1.14b) to EBITDA (276.4m): 4.13 < 3 |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (166.2m) vs 12m ago -1.51% < -2% |
| Gross Margin: 86.63% > 18% (prev 84.42%; Δ 2.22% > 0.5%) |
| Asset Turnover: 49.28% > 50% (prev 72.71%; Δ -23.42% > 0%) |
| Interest Coverage Ratio: 7.15 > 6 (EBIT TTM 237.2m / Interest Expense TTM 33.2m) |
| A: 0.18 (Total Current Assets 1.36b - Total Current Liabilities 599.5m) / Total Assets 4.26b |
| B: -0.19 (Retained Earnings -801.3m / Total Assets 4.26b) |
| C: 0.07 (EBIT TTM 237.2m / Avg Total Assets 3.17b) |
| D: 0.70 (Book Value of Equity 1.75b / Total Liabilities 2.51b) |
| Altman-Z'' = 1.79 = BBB |
| DSRI: 1.23 (Receivables 407.6m/321.8m, Revenue 1.56b/1.51b) |
| GMI: 0.97 (GM 84.42% / 86.63%) |
| AQI: 4.44 (AQ_t 0.61 / AQ_t-1 0.14) |
| SGI: 1.03 (Revenue 1.56b / 1.51b) |
| TATA: -0.02 (NI 152.7m - CFO 256.2m) / TA 4.26b) |
| Beneish M = -0.80 (Cap -4..+1) = D |
As of July 14, 2026, the stock is trading at USD 51.87 with a total of 1,561,418 shares traded. Over the past week, the price has changed by -5.93%, over one month by +16.93%, over three months by +53.69% and over the past year by +74.71%.
Current recommended Stop Loss: 49.40 (which is 4.8% or 1.2 ATR below the current price).
Alkermes has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ALKS.
- StrongBuy: 8
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.6 | -2.5% |
P/E Trailing = 60.4828
P/E Forward = 142.8571
P/S = 5.7376
P/B = 5.1662
P/EG = 1.9605
Revenue TTM = 1.56b USD
EBIT TTM = 237.2m USD
EBITDA TTM = 276.4m USD
Long Term Debt = 1.48b USD (from longTermDebt, last quarter)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 1.65b USD (from shortLongTermDebtTotal, last quarter) + Leases 71.3m
Net Debt = 1.14b USD (calculated: Debt 1.65b - CCE 511.9m)
Enterprise Value = 9.91b USD (8.77b + Debt 1.65b - CCE 511.9m)
Interest Coverage Ratio = 7.15 (Ebit TTM 237.2m / Interest Expense TTM 33.2m)
EV/FCF = 44.69x (Enterprise Value 9.91b / FCF TTM 221.8m)
FCF Yield = 2.24% (FCF TTM 221.8m / Enterprise Value 9.91b)
FCF Margin = 14.20% (FCF TTM 221.8m / Revenue TTM 1.56b)
Net Margin = 9.78% (Net Income TTM 152.7m / Revenue TTM 1.56b)
Gross Margin = 86.63% ((Revenue TTM 1.56b - Cost of Revenue TTM 208.8m) / Revenue TTM)
Gross Margin QoQ = 84.33% (prev 87.98%)
Tobins Q-Ratio = 2.33 (Enterprise Value 9.91b / Total Assets 4.26b)
Interest Expense / Debt = 2.01% (Interest Expense 33.2m / Debt 1.65b)
Taxrate = 25.15% (51.3m / 204.0m)
NOPAT = 177.5m (EBIT 237.2m * (1 - 25.15%))
Current Ratio = 2.27 (Total Current Assets 1.36b / Total Current Liabilities 599.5m)
Debt / Equity = 0.94 (Debt 1.65b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 4.13 (Net Debt 1.14b / EBITDA 276.4m)
Debt / FCF = 5.14 (Net Debt 1.14b / FCF TTM 221.8m)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.82% (Net Income 152.7m / Total Assets 4.26b)
RoE = 8.82% (Net Income TTM 152.7m / Total Stockholder Equity 1.73b)
RoCE = 7.38% (EBIT 237.2m / Capital Employed (Equity 1.73b + L.T.Debt 1.48b))
RoIC = 4.91% (NOPAT 177.5m / Invested Capital 3.61b)
WACC = 7.27% (E(8.77b)/V(10.4b) * Re(8.36%) + D(1.65b)/V(10.4b) * Rd(2.01%) * (1-Tc(0.25)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -66.16 | Cagr: -1.05%
[DCF] Terminal Value 73.10% ; FCFF base≈325.7m ; Y1≈285.6m ; Y5≈230.8m
[DCF] Fair Price = 15.38 (EV 3.70b - Net Debt 1.14b = Equity 2.56b / Shares 166.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 70.36 | EPS CAGR: 36.38% | SUE: 2.36 | # QB: 1
Revenue Correlation: -31.01 | Revenue CAGR: -1.67% | SUE: 1.27 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=-43.73% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.24 | Chg30d=-33.27% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.98 | Chg30d=-31.34% | Revisions=+0% | GrowthEPS=-53.1% | GrowthRev=+22.6%
EPS next Year (2027-12-31): EPS=1.56 | Chg30d=-33.90% | Revisions=+25% | GrowthEPS=+58.2% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +25% (up=1, down=0)